PTC Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PTC Therapeutics announced the approval of inducement grants for nineteen new employees on Oct. 23, 2024. The grants include 13,690 non-statutory stock options and 20,250 restricted stock units (RSUs). The stock options have an exercise price of $42.48 per share, vesting over four years with 25% vesting after the first year and 6.25% quarterly thereafter. The RSUs also vest over four years, with 25% vesting annually. These awards were granted under Nasdaq Listing Rule 5635(c)(4) as part of the new employees' compensation packages.
PTC Therapeutics ha annunciato l'approvazione di incentivi per diciannove nuovi dipendenti il 23 ottobre 2024. Gli incentivi comprendono 13.690 opzioni su azioni non statutarie e 20.250 unità di azioni vincolate (RSU). Le opzioni su azioni hanno un prezzo di esercizio di $42,48 per azione, con un periodo di maturazione di quattro anni, con il 25% che matura dopo il primo anno e il 6,25% trimestralmente successivamente. Anche le RSU maturano in quattro anni, con il 25% che matura annualmente. Questi premi sono stati concessi in base alla Regola di quotazione Nasdaq 5635(c)(4) come parte dei pacchetti di compensazione per i nuovi dipendenti.
PTC Therapeutics anunció la aprobación de incentivos para diecinueve nuevos empleados el 23 de octubre de 2024. Los incentivos incluyen 13,690 opciones de acciones no estatutarias y 20,250 unidades de acciones restringidas (RSUs). Las opciones de acciones tienen un precio de ejercicio de $42.48 por acción, con un periodo de adquisición de cuatro años, con el 25% adquiriéndose después del primer año y un 6.25% trimestralmente después. Las RSUs también se adquieren durante cuatro años, con un 25% que se adquiere anualmente. Estos premios se otorgaron según la Regla de Cotización de Nasdaq 5635(c)(4) como parte de los paquetes de compensación de los nuevos empleados.
PTC Therapeutics는 2024년 10월 23일에 19명의 신규 직원을 위한 유인 보조금 승인을 발표했습니다. 보조금에는 13,690개의 비정관적 주식 옵션과 20,250개의 제한된 주식 단위(RSU)가 포함됩니다. 주식 옵션의 행사 가격은 $42.48 per 주식이며, 4년 동안 25%가 첫해에 배분되고 이후 매 분기마다 6.25%가 배분됩니다. RSU도 4년에 걸쳐 배분되며 매년 25%가 배분됩니다. 이 보상은 Nasdaq 상장 규칙 5635(c)(4)에 따라 신규 직원의 보상 패키지의 일환으로 제공되었습니다.
PTC Therapeutics a annoncé l'approbation de subventions d'incitation pour dix-neuf nouveaux employés le 23 octobre 2024. Les subventions comprennent 13.690 options d'actions non statutaires et 20.250 unités d'actions restreintes (RSU). Les options d'actions ont un prix d'exercice de 42,48 $ par action, avec une période d'acquisition de quatre ans, 25 % étant acquis après la première année et 6,25 % de manière trimestrielle par la suite. Les RSU sont également acquises sur quatre ans, avec 25 % acquis chaque année. Ces distinctions ont été accordées en vertu de la règle de cotation Nasdaq 5635(c)(4) dans le cadre des paquets de rémunération des nouveaux employés.
PTC Therapeutics gab am 23. Oktober 2024 die Genehmigung von Anreizvergaben für neunzehn neue Mitarbeiter bekannt. Die Anreize umfassen 13.690 nicht-statutäre Aktienoptionen und 20.250 beschränkte Aktieneinheiten (RSUs). Die Aktienoptionen haben einen Ausübungspreis von 42,48 $ pro Aktie, der über vier Jahre verteilt wird, wobei 25 % nach dem ersten Jahr und anschließend vierteljährlich 6,25 % fällig werden. Auch die RSUs werden über vier Jahre verteilt, wobei jährlich 25 % fällig werden. Diese Auszeichnungen wurden gemäß der Nasdaq-Listing-Regel 5635(c)(4) als Teil der Vergütungspakete der neuen Mitarbeiter gewährt.
- Company demonstrates ability to attract new talent with equity compensation
- Stock options granted at market price ($42.48), aligning employee interests with shareholders
- Potential shareholder dilution from issuance of 33,940 new shares (options and RSUs combined)
The inducement grants were approved by PTC's Compensation Committee on Oct. 23, 2024, and are being made as an inducement material to each employee's acceptance of employment with the company in accordance with Nasdaq Listing Rule 5635(c)(4).
All stock option awards have an exercise price of
ABOUT PTC THERAPEUTICS, INC.
PTC is a science-driven, global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. PTC's ability to innovate to identify new therapies and to globally commercialize products is the foundation that drives investment in a robust and diversified pipeline of transformative medicines. PTC's mission is to provide access to best-in-class treatments for patients who have little to no treatment options. PTC's strategy is to leverage its strong scientific and clinical expertise and global commercial infrastructure to bring therapies to patients. PTC believes this allows it to maximize value for all its stakeholders. To learn more about PTC, please visit us at www.ptcbio.com and follow us on Instagram, Facebook, Twitter, and LinkedIn.
For more information please contact:
Jeanine Clemente
+1 (908) 912-9406
jclemente@ptcbio.com
View original content:https://www.prnewswire.com/news-releases/ptc-therapeutics-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-302287599.html
SOURCE PTC Therapeutics, Inc.
FAQ
How many stock options and RSUs did PTC Therapeutics (PTCT) grant on October 23, 2024?
What is the exercise price for PTCT's October 2024 stock option grants?
What is the vesting schedule for PTCT's October 2024 inducement grants?
